BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38508120)

  • 1. Evaluation of novel 2-(quinoline-2-ylthio)acetamide derivatives linked to diphenyl-imidazole as α-glucosidase inhibitors: Insights from in silico, in vitro, and in vivo studies on their anti-diabetic properties.
    Khalili Ghomi M; Noori M; Mirahmad M; Iraji A; Sadr AS; Dastyafteh N; Asili P; Gholami M; Javanshir S; Lotfi M; Mojtabavi S; Faramarzi MA; Asadi M; Nasli-Esfahani E; Palimi M; Larijani B; Meshkatalsadat MH; Mahdavi M
    Eur J Med Chem; 2024 Apr; 269():116332. PubMed ID: 38508120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and in silico studies of quinoline-based-benzo[d]imidazole bearing different acetamide derivatives as potent α-glucosidase inhibitors.
    Noori M; Davoodi A; Iraji A; Dastyafteh N; Khalili M; Asadi M; Mohammadi Khanaposhtani M; Mojtabavi S; Dianatpour M; Faramarzi MA; Larijani B; Amanlou M; Mahdavi M
    Sci Rep; 2022 Aug; 12(1):14019. PubMed ID: 35982225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro potency of inhibition, enzyme kinetics and in silico studies of quinoline-based α-glucosidase inhibitors.
    Ghomi MK; Dastyafteh N; Montazer MN; Noori M; Mojtabavi S; Faramarzi MA; Hashemi SM; Mahdavi M
    Sci Rep; 2024 Jan; 14(1):501. PubMed ID: 38177164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-glucosidase inhibitory and hypoglycemic effects of imidazole-bearing thioquinoline derivatives with different substituents: In silico, in vitro, and in vivo evaluations.
    Azmi A; Noori M; Khalili Ghomi M; Nazari Montazer M; Iraji A; Dastyafteh N; Oliyaei N; Khoramjouy M; Rezaei Z; Javanshir S; Mojtabavi S; Faramarzi MA; Asadi M; Faizi M; Mahdavi M
    Bioorg Chem; 2024 Mar; 144():107106. PubMed ID: 38244380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation.
    Li Y; Zhang JH; Xie HX; Ge YX; Wang KM; Song ZL; Zhu KK; Zhang J; Jiang CS
    Bioorg Chem; 2021 Dec; 117():105423. PubMed ID: 34717239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Coumarin Containing Dithiocarbamate Derivatives as Potent α-Glucosidase Inhibitors for Management of Type 2 Diabetes.
    Mollazadeh M; Mohammadi-Khanaposhtani M; Valizadeh Y; Zonouzi A; Faramarzi MA; Kiani M; Biglar M; Larijani B; Hamedifar H; Mahdavi M; Hajimiri MH
    Med Chem; 2021; 17(3):264-272. PubMed ID: 32851964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation.
    Xie HX; Zhang J; Li Y; Zhang JH; Liu SK; Zhang J; Zheng H; Hao GZ; Zhu KK; Jiang CS
    Bioorg Chem; 2021 Oct; 115():105236. PubMed ID: 34411978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coumarin linked to 2-phenylbenzimidazole derivatives as potent α-glucosidase inhibitors.
    Ganjeh MS; Mazlomifar A; Shahvelayti AS; Moghaddam SK
    Sci Rep; 2024 Mar; 14(1):7408. PubMed ID: 38548784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrano[3,2-c]quinoline Derivatives as New Class of α-glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in vitro Biological Evaluation and Kinetic Study.
    Heydari Z; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Mahdavi M; Ranjbar PR; Larijani B
    Med Chem; 2019; 15(1):8-16. PubMed ID: 29807519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents.
    Nikookar H; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Ranjbar PR; Mahdavi M; Larijani B
    Bioorg Chem; 2018 Apr; 77():280-286. PubMed ID: 29421703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aryl-quinoline-4-carbonyl hydrazone bearing different 2-methoxyphenoxyacetamides as potent α-glucosidase inhibitors; molecular dynamics, kinetic and structure-activity relationship studies.
    Hamedifar H; Mirfattahi M; Khalili Ghomi M; Azizian H; Iraji A; Noori M; Moazzam A; Dastyafteh N; Nokhbehzaim A; Mehrpour K; Javanshir S; Mojtabavi S; Faramarzi MA; Larijani B; Hajimiri MH; Mahdavi M
    Sci Rep; 2024 Jan; 14(1):388. PubMed ID: 38172167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase.
    Yousefnejad F; Mohammadi-Moghadam-Goozali M; Sayahi MH; Halimi M; Moazzam A; Mohammadi-Khanaposhtani M; Mojtabavi S; Asadi M; Faramarzi MA; Larijani B; Amanlou M; Mahdavi M
    Sci Rep; 2023 Jul; 13(1):12397. PubMed ID: 37524733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of α-glucosidase inhibitors.
    Iraji A; Shareghi-Brojeni D; Mojtabavi S; Faramarzi MA; Akbarzadeh T; Saeedi M
    Sci Rep; 2022 May; 12(1):8647. PubMed ID: 35606520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides as potential anti-diabetic agents.
    Emadi M; Halimi M; Moazzam A; Hosseini S; Mojtabavi S; Faramarzi MA; Ghadimi R; Moghadamnia AA; Nasli-Esfahani E; Mohammadi-Khanaposhtani M; Mahdavi M
    Sci Rep; 2023 Jun; 13(1):10030. PubMed ID: 37340010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphenyl-substituted triazine derivatives: synthesis, α-glucosidase inhibitory activity, kinetics and
    Shamim S; Khan KM; Ali M; Mahdavi M; Salar U; Mohammadi-Khanaposhtani M; Faramarzi MA; Ullah N; Taha M
    Future Med Chem; 2023 Sep; 15(18):1651-1668. PubMed ID: 37727987
    [No Abstract]   [Full Text] [Related]  

  • 16. 2,5-Disubstituted furan derivatives containing imidazole, triazole or tetrazole moiety as potent α-glucosidase inhibitors.
    He M; Li YJ; Shao J; Fu C; Li YS; Cui ZN
    Bioorg Chem; 2023 Feb; 131():106298. PubMed ID: 36455481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new entry into the portfolio of α-glucosidase inhibitors as potent therapeutics for type 2 diabetes: Design, bioevaluation and one-pot multi-component synthesis of diamine-bridged coumarinyl oxadiazole conjugates.
    Kazmi M; Zaib S; Ibrar A; Amjad ST; Shafique Z; Mehsud S; Saeed A; Iqbal J; Khan I
    Bioorg Chem; 2018 Apr; 77():190-202. PubMed ID: 29421697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, in vitro evaluation and molecular docking studies of novel coumarin-isatin derivatives as α-glucosidase inhibitors.
    Wang G; Wang J; He D; Li X; Li J; Peng Z
    Chem Biol Drug Des; 2017 Mar; 89(3):456-463. PubMed ID: 27616456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of new benzimidazole-1,2,3-triazole hybrids as potential α-glucosidase inhibitors.
    Asemanipoor N; Mohammadi-Khanaposhtani M; Moradi S; Vahidi M; Asadi M; Faramarzi MA; Mahdavi M; Biglar M; Larijani B; Hamedifar H; Hajimiri MH
    Bioorg Chem; 2020 Jan; 95():103482. PubMed ID: 31838286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Molecular Docking Studies of Alkoxy- and Imidazole-Substituted Xanthones as α-Amylase and α-Glucosidase Inhibitors.
    Aguila-Muñoz DG; Vázquez-Lira G; Sarmiento-Tlale E; Cruz-López MC; Jiménez-Montejo FE; López Y López VE; Escalante CH; Andrade-Pavón D; Gómez-García O; Tamariz J; Mendieta-Moctezuma A
    Molecules; 2023 May; 28(10):. PubMed ID: 37241920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.